STOCK TITAN

Verona Pharma Plc - VRNA STOCK NEWS

Welcome to our dedicated news page for Verona Pharma Plc (Ticker: VRNA), a resource for investors and traders seeking the latest updates and insights on Verona Pharma Plc.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Verona Pharma Plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Verona Pharma Plc's position in the market.

Rhea-AI Summary
Verona Pharma announces Investor Update in New York City
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.4%
Tags
conferences
-
Rhea-AI Summary
Verona Pharma announces positive results from Phase 3 ENHANCE studies with ensifentrine for COPD treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.71%
Tags
conferences clinical trial
-
Rhea-AI Summary
Verona Pharma announces FDA acceptance of NDA for ensifentrine, with a target action date of June 26, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.27%
Tags
none
Rhea-AI Summary
Verona Pharma announces positive results from Phase 3 ENHANCE-1 study with ensifentrine for COPD treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.23%
Tags
conferences clinical trial
-
Rhea-AI Summary
Verona Pharma appoints Christina Ackermann as Non-Executive Director
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.03%
Tags
none
-
Rhea-AI Summary
Verona Pharma submits NDA for ensifentrine for COPD treatment. Phase 3 data published. Strong balance sheet. Conference call scheduled.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.88%
Tags
earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.66%
Tags
conferences
-
Rhea-AI Summary
Verona Pharma plc will report its financial results for Q2 2023 on August 3, 2023. An investment community conference call will be held to discuss the results and provide a corporate update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.91%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.67%
Tags
clinical trial
Rhea-AI Summary
Verona Pharma submits New Drug Application for approval of ensifentrine for the treatment of COPD
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.03%
Tags
none
Verona Pharma Plc

Nasdaq:VRNA

VRNA Rankings

VRNA Stock Data

1.30B
440.24M
4.28%
85.25%
7.9%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United Kingdom
3 More London Place

About VRNA

verona pharma is a clinical stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. we are currently focused on developing our novel lead therapeutic candidate in the treatment of chronic obstructive pulmonary fibrosis (copd) and cystic fibrosis (cf), and may expand our pipeline to help address the gaps in treatment of other respiratory diseases. we are led by a team with deep industry experience, including extensive backgrounds in the discovery, development and commercialization of respiratory therapies. in addition, we have established relationships with leading research institutions and advocacy organizations in the respiratory space and have received awards in support of our continued work and innovation. verona pharma is listed on the nasdaq global market in the united states under the ticker symbol vrna and on the london stock exchange in the united kin